Viewing StudyNCT00295932



Ignite Creation Date: 2024-05-05 @ 4:41 PM
Last Modification Date: 2024-10-26 @ 9:23 AM
Study NCT ID: NCT00295932
Status: COMPLETED
Last Update Posted: 2018-11-20
First Post: 2006-02-23

Brief Title: Bortezomib Rituximab Cyclophosphamide and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Organization: Memorial Sloan Kettering Cancer Center

Organization Data

Organization: Memorial Sloan Kettering Cancer Center
Class: OTHER
Study ID: 05-103
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Lead Sponsor Class: OTHER
Responsible Party: None
Responsible Party Title: None
Responsible Party Type: SPONSOR
Responsible Party Affiliation: None
Old Name: None
Old Organization: None

Collaborators

Name Class
Emory University OTHER
National Cancer Institute NCI NIH
Rutgers Cancer Institute of New Jersey OTHER
Columbia University OTHER